Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myron J Levin

Showing results (11-20 of 186) with videos related to

Pageof 19
Sort By:
Human Vaccines & Immunotherapeutics|January 19, 2012
The rationale for quadrivalent influenza vaccinesChristopher S Ambrose, Myron J Levin
Current Opinion in Virology|October 11, 2011
Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerIan H Frazer, Myron J Levin
The Journal of Infectious Diseases|September 25, 2018
Herpes Zoster VaccinesAnthony L Cunningham, Myron J Levin
Interdisciplinary Topics in Gerontology and Geriatrics|April 20, 2020
Herpes Zoster and Its Prevention by VaccinationRobert W Johnson, Myron J Levin
The American Journal of Medicine|September 28, 2016
Shedding Light on Shingles: The Power of PreventionLawrence Herman, Myron J Levin, Susan Rehm
Vaccine|November 6, 2007
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adultsJames M Pellissier, Marc Brisson, Myron J Levin
Human Vaccines|April 8, 2010
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adultsAdriana Weinberg, Myron J Levin, Rob Roy Macgregor
Microbiology Spectrum|June 24, 2016
Herpes Simplex Virus and Varicella-Zoster VirusMyron J Levin, Adriana Weinberg, D Scott Schmid
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 9, 2007
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgiaMarc Brisson, James M Pellissier, Myron J Levin
Journal of Biopharmaceutical Statistics|February 11, 2005
Responder cell frequency estimation and binomial three-level nonlinear mixed effects model in limiting dilution assaysMisoo C Ellison, Gary O Zerbe, Myron J Levin
Pageof 19

Showing results (11-20 of 186) with videos related to

Sort By:
Pageof 19
Human Vaccines & Immunotherapeutics|January 19, 2012
The rationale for quadrivalent influenza vaccinesChristopher S Ambrose, Myron J Levin
Current Opinion in Virology|October 11, 2011
Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerIan H Frazer, Myron J Levin
The Journal of Infectious Diseases|September 25, 2018
Herpes Zoster VaccinesAnthony L Cunningham, Myron J Levin
Interdisciplinary Topics in Gerontology and Geriatrics|April 20, 2020
Herpes Zoster and Its Prevention by VaccinationRobert W Johnson, Myron J Levin
The American Journal of Medicine|September 28, 2016
Shedding Light on Shingles: The Power of PreventionLawrence Herman, Myron J Levin, Susan Rehm
Vaccine|November 6, 2007
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adultsJames M Pellissier, Marc Brisson, Myron J Levin
Human Vaccines|April 8, 2010
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adultsAdriana Weinberg, Myron J Levin, Rob Roy Macgregor
Microbiology Spectrum|June 24, 2016
Herpes Simplex Virus and Varicella-Zoster VirusMyron J Levin, Adriana Weinberg, D Scott Schmid
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 9, 2007
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgiaMarc Brisson, James M Pellissier, Myron J Levin
Journal of Biopharmaceutical Statistics|February 11, 2005
Responder cell frequency estimation and binomial three-level nonlinear mixed effects model in limiting dilution assaysMisoo C Ellison, Gary O Zerbe, Myron J Levin
Pageof 19